key: cord-0757621-pnkrdkmg authors: Pawankar, Ruby; Thong, Bernard Yu-Hor; Wang, Jiu-Yao title: APAAACI 2021 International Conference: a new era of allergy and clinical immunology in digital date: 2022-01-18 journal: Asia Pac Allergy DOI: 10.5415/apallergy.2022.12.e5 sha: 68d4910153004242652b880a6c8acf606df6c21f doc_id: 757621 cord_uid: pnkrdkmg nan Phenotyping and endotyping allergic diseases are key to the diagnosis and management of severe refractory disease, more commonly in adults than children. This is particularly relevant in disorders of the upper and lower airways (chronic rhinosinusitis with/without nasal polyposis [4] and severe/ difficult asthma [5] ) and skin (atopic dermatitis [6] and chronic urticaria [7] ). The patient's demographic profile, clinical presentation, and clinical course determine the phenotype; whereas biomarkers in the peripheral blood e.g., eosinophils, IgE, Th2 high proinflammatory cytokines e.g., interleukin (IL)-4, IL-5, IL-13, pattern of inflammatory infiltrate within affected tissue e.g., nasal polyps, form the basis of the endotype. Targeted biologics e.g., omalizumab (anti-IgE), dupilumab (anti-IL-4 receptor alpha antibody), mepolizumab (anti-IL5) and benralizumab (anti-IL5 receptor antibody) specific for certain disease phenotype and endotype thus forms the basis of "personalized" or "precision medicine" [8] . This was extensively covered in the plenary and symposia on biologics in allergic disease, asthma, rhinitis, and atopic dermatitis. Even AIT [9] used in airway allergy and food allergy (oral immunotherapy) is also a form of evidence-based precision medicine, potentially guided by artificial intelligence [10] . Characteristics of COVID-19, treatment strategies and COVID-19 vaccinations are key focuses of APAAACI's COVID-19 Task Force [11] highlighted also during the APAAACI Allergy week 2021 in collaboration with the World Health Organization. Symposia covering COVID-19 epidemiological differences in the region, emerging therapies beyond dexamethasone and remdesivir e.g., immunomodulatory agents (e.g., baricitinib), postexposure prophylaxis with anti-SARS-CoV-2 monoclonal antibodies (e.g., sotrovimab, casirivamab plus imdevimab) and primary vaccinations were among the key sessions. COVID-19 vaccinations are available in the Asia-Pacific region through pandemic special access routes, using different platforms e.g., mRNA (Pfizer-Comirnaty, Moderna), inactivated virus (CoronaVac), adenovirus vector vaccines (Oxford-Astra-Zeneca, Janssen/ Johnson & Johnson), protein-subunit for immunoglobulin (Novavax). As the SARS-CoV-2 virus continues to mutate within vaccinated and unvaccinated communities into variants of concern e.g., Delta, Omicron [12] , increase health care needs, new infection control measures, new diagnostics and therapeutics will emerge [13] . The rates of mRNA vaccine associated anaphylaxis has significantly reduced globally as the number vaccinated worldwide increase exponentially [14] . The APAAACI 2022, PSAAI@50, Drug Hypersensitivity and Desensitization, Autoimmunity symposiums each had lectures addressing various facets of COVID-19 vaccines. Early life microbial exposures and allergy risks: opportunities for prevention The maternal gut microbiome during pregnancy and offspring allergy and asthma Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Chronic rhinosinusitis in Asia Large-scale plasma proteomics can reveal distinct endotypes in chronic obstructive pulmonary disease and severe asthma Advances in atopic dermatitis in 2019-2020: endotypes from skin barrier, ethnicity, properties of antigen, cytokine profiles, microbiome, and engagement of immune cells The international EAACI/GA 2 LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria Achieving precision medicine in allergic disease: progress and challenges Personalized medicine and allergen immunotherapy: the beginning of a new era Artificial intelligence in the diagnosis of pediatric allergic diseases Asia-Pacific perspectives on the COVID-19 pandemic Omicron (B.1.1.529) -variant of concern -molecular profile and epidemiology: a mini review Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy COVID-19 mRNA vaccine allergy Asia Pacific Association of Allergy Asthma and Clinical Immunology White Paper 2020 on climate change, air pollution, and biodiversity in Asia-Pacific and impact on allergic diseases The authors have no financial conflicts of interest.